Syndax Pharmaceuticals, Inc.(SNDX) Stock Research - Grey Stern Research

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis

$19.10 (-2.55%)

SNDX Financial Performance


Use the table below to view Syndax Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $19.60 -
52 Week Low $11.22 -
52 Week High $25.34 -
Market Cap $1.7 Billion 9/19
Gross Margin 100% 1/19
Profit Margin -100% 13/19
EBITDA margin -2120% 16/19
Q2 - 2024 Revenue $3.5 Million 3/19
Q2 - 2024 Earnings -$68.1 Million 15/19
Q2 - 2024 Free Cash Flow -$71.6 Million 15/19
Trailing 4 Quarters Revenue $4.0 Million 6/19
Trailing 4 Quarters Earnings -$269.0 Million 15/19
Quarterly Earnings Growth -53% 13/19
Annual Earnings Growth -76% 16/19
Quarterly Revenue Growth 0% 2/19
Annual Revenue Growth 0% 3/19
Cash On Hand $105.4 Million 10/19
Short Term Debt $993,000 14/19
Long Term Debt $0 17/19

Syndax Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Syndax Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/19
PS 413.25 7/19
PB 3.84 10/19
PC 15.82 9/19
Liabilities to Equity 0.10 13/19
ROA -0.56 16/19
ROE -0.62 14/19
Current Ratio 11.19 7/19
Quick Ratio 9.98 8/19
Long Term Debt to Equity 0.00 16/19
Debt to Equity 0.00 19/19
Burn Rate 1.54 12/19
Cash to Cap 0.06 11/19
CCR 1.05 2/19
EV to EBITDA -21.07 13/19
EV to Revenue 387.42 7/19

Company Details

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

CEO: Dr. Briggs Morrison

Website: https://www.syndax.com

Address: Building D, 35 Gatehouse Dr Fl 3 Waltham, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Biotechnology

Syndax Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Syndax Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dyne Therapeutics, Inc. DYN $3.3 Billion
Cogent Biosciences, Inc. COGT $1.1 Billion
Cytokinetics, Incorporated CYTK $6.4 Billion
Mersana Therapeutics, Inc. MRSN $165.6 Million
Merus N.V. MRUS $3.4 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Replimune Group, Inc. REPL $708.5 Million
Sutro Biopharma, Inc. STRO $337.7 Million
Revolution Medicines, Inc. RVMD $7.0 Billion
Keros Therapeutics, Inc. KROS $2.0 Billion
Larimar Therapeutics, Inc. LRMR $513.6 Million
Pliant Therapeutics, Inc. PLRX $782.5 Million
Vaxcyte, Inc. PCVX $12.5 Billion
Inozyme Pharma, Inc. INZY $312.4 Million
Edgewise Therapeutics, Inc. EWTX $1.6 Billion
Viridian Therapeutics, Inc. VRDN $900.2 Million
Aerovate Therapeutics, Inc. AVTE $54.8 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SNDX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 3.5 Million -$68.1 Million
Q1 2024 $ 0 -$72.4 Million
Q4 2023 $ 536,000 -$77.4 Million
Q3 2023 $ 0 -$51.1 Million
Q2 2023 $ 0 -$44.6 Million
Q1 2023 $ 0 -$36.2 Million
Q4 2022 $ 0 -$36.3 Million
Q3 2022 $ 0 -$35.4 Million

View All

SNDX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $105.4 Million $476.9 Million $1.1 Million $434.3 Million
Q1 2024 $114.6 Million $543.0 Million $1.4 Million $491.9 Million
Q4 2023 $295.4 Million $612.9 Million $0 $554.2 Million
Q3 2023 $94.6 Million $399.2 Million $0 $359.2 Million
Q2 2023 $97.3 Million $431.3 Million $2.1 Million $400.0 Million
Q1 2023 $57.5 Million $459.8 Million $1.1 Million $435.5 Million
Q4 2022 $74.4 Million $497.2 Million $1.2 Million $467.4 Million
Q3 2022 $71.4 Million $359.7 Million $0 $338.1 Million

View All

SNDX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$71.6 Million $0 -$9.2 Million
Q1 2024 -$83.5 Million $0 -$180.8 Million
Q4 2023 -$41.3 Million $0 $200.8 Million
Q3 2023 $0 $0 $0
Q2 2023 -$35.4 Million $0 $39.9 Million
Q1 2023 -$39.2 Million $0 -$16.8 Million
Q4 2022 -$22.9 Million $0 $3.0 Million
Q3 2022 -$28.5 Million $0 -$48.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions